ACADIA Pharmaceuticals Inc. (LON:0A4W)

Market Cap	2.63B
Revenue (ttm)	693.30M
Net Income (ttm)	95.88M
Shares Out	n/a
EPS (ttm)	0.58
PE Ratio	27.39
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	3,241
Average Volume	2,167
Open	18.75
Previous Close	18.64
Day's Range	18.62 - 18.97
52-Week Range	11.26 - 25.25
Beta	n/a
RSI	58.25
Earnings Date	Feb 27, 2025

About ACADIA Pharmaceuticals

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome. It also develops Pimavanserin tha...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1993
• Employees: 598
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0A4W

Financial Performance

In 2023, ACADIA Pharmaceuticals's revenue was $726.44 million, an increase of 40.45% compared to the previous year's $517.24 million. Losses were -$61.29 million, -71.62% less than in 2022.

Financial numbers in USD